Diaceutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Diaceutics şirketinin toplam hissedar öz sermayesi £38.7M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £45.4M ve £6.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£16.75m
Eşitlik	UK£38.74m
Toplam yükümlülükler	UK£6.69m
Toplam varlıklar	UK£45.43m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 7DC 'nin kısa vadeli varlıkları ( £27.2M ) kısa vadeli yükümlülüklerini ( £5.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: 7DC şirketinin kısa vadeli varlıkları ( £27.2M ) uzun vadeli yükümlülüklerini ( £1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 7DC borçsuzdur.

Borcun Azaltılması: 7DC şirketinin 5 yıl önce borç/öz sermaye oranı 0.6% iken borcu yok.

Borç Kapsamı: 7DC un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 7DC şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Diaceutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Now 20% overvalued

Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People Officer

Less than half of directors are independent

Diaceutics plc Announces Board Changes

First half 2024 earnings released: UK£0.031 loss per share (vs UK£0.018 loss in 1H 2023)

Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024

Diaceutics PLC Launches Enhanced Rare-Disease Offering

Diaceutics PLC Announces Launch of PMx

Diaceutics plc Announces Board Changes

Independent Non-Executive Director recently bought €60k worth of stock

Full year 2023 earnings released

Diaceutics PLC Launches Significant Upgrade to Its DXRX Platform

Diaceutics PLC, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

Less than half of directors are independent

First half 2023 earnings released: UK£0.018 loss per share (vs UK£0.009 loss in 1H 2022)

New minor risk - Profit margin trend

Diaceutics Announces Executive Changes

Diaceutics PLC Announces Executive Changes, Effective 1 October 2023

Diaceutics plc Launches Daily Alerts for Dxrx Platform

Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023

Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021)

Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medicine and Its Impact on Cancer Patients

First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021)

Diaceutics PLC to Report First Half, 2022 Results on Sep 27, 2022

Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX Platform

No independent directors

Executive Officer recently sold €237k worth of stock

Diaceutics PLC Announces Test Signal Launch and Contract Wins

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020)

Diaceutics PLC Provides Earnings Guidance for the Year 2021

Chief Commercial Officer recently sold €73k worth of stock

CFO & Executive Director recently sold €284k worth of stock

Full year 2020 earnings released

Diaceutics PLC Appoints Nikita Lynn as Vice President of Finance

Investor sentiment improved over the past week

Diaceutics PLC to Report Fiscal Year 2020 Results on Mar 15, 2021

Investor sentiment improved over the past week

Diaceutics PLC Announces the Resignation of Julie Goonewardene as Non-Executive Chair, with Effect from December 31, 2020

Diaceutics and Alva10 Partner to Deliver Value-Based Test Reimbursement Model for US Payers, Pharma and Testing Providers Via Dxrx Platform

Diaceutics PLC Launches Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

Market pulls back on stock over the past week

Diaceutics PLC Partners with Global EQA Providers to Implement Best-In-Class Testing Standards

New 90-day high - €2.12

Diaceutics PLC announced that it has received £4 million in funding from SVB Silicon Valley Bank, Investment Arm

New 90-day high - €2.04

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin